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Brief Background: Streptococcus mutans (S.mutans) is the pioneering pathogenic bacteria 
responsible for the initiation of dental caries. Controlling S.mutans activity using dental 
probiotics may have an impact on caries incidence and oral health in general.   
Objective: To evaluate the effects of commercially available dental probiotics (PRO-
Dental, Hyperbiotics Inc.) usage for 60 days in a row on the cariogenic bacterium S.mutans 
in high caries risk patients with high or low S.mutans counts at baseline and 30 days after 
the discontinuation of use. 
Methodology: A total of 30 consenting adult patients with high caries risk (according to 
NSU CAMBRA protocol) without any complex medical history or recent antibiotic usage 
were recruited after IRB approval. Standardized oral hygiene instructions and oral hygiene 
care kit were given to all patients after a periodontal cleaning. Baseline saliva sampling 
was performed. Patients were given 60 day supply of dental probiotic tablets containing 
live bacteria of S.salivarius K12, S.salivarius M18, L.reuteri, L.paracasei, and zinc (PRO-
Dental) following the manufacturer’s instructions (1tablet/day, before bed). After 30 days, 
vi 
 
patients were recalled for saliva sampling, and they were instructed to continue using 
probiotics. Upon completion of probiotic dose (60-days), the subjects were recalled for 
saliva sampling. After 30 days of probiotics discontinuation, patients were recalled for the 
last saliva collection. Saliva samples were collected at each time by chewing a paraffin 
wax to stimulate salivation (1ml). The samples were then diluted to 100, 1000, and 10,000 
times in phosphate-buffered saline. Resulting serially-diluted bacterial suspensions were 
inoculated to a mitis-salivarius-bacitracin-potassium-tellurite agar plate and incubated in 
an anaerobic jar at 37°C for 48h. S.mutans colonies observed on the agar plate were counted 
using colony-forming units (CFU) per ml of stimulated saliva. The results were statistically 
analyzed using Pairwise comparisons with Bonferroni adjustment of margins was used to 
look for specific differences across time periods, and Poisson distribution was conducted 
to account for the data measurement scale. Statistical significance was found at p<0.05. 
Results: Across all cell counts of 100, 1000, 10000, and baseline, significant differences 
were found across time (p < 0.05). S.mutans count decreased by %48.5 after 30 days and 
by %83.9 after 60 days of probiotic usage. After 30 days of probiotic discontinuation. 
S.mutans counts got increased by %14.4. The continued suppression of the S.mutans for 
30 days was statistically significant (p < 0.05), it reduced by %69.5 from the baseline. 
Compliance was 100%, with no adverse events.  
Conclusion: The daily administration of dental probiotics for 60 days sufficiently 
suppressed the level of oral S.mutans and suppression continued for 30 more days. Further 
long-term research is needed to evaluate the sustainability of probiotics on the continued 
suppression of this cariogenic bacterium.  
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Chapter 1: Introduction 
1.1 Probiotics 
1.1.1 History 
The first concept of probiotics was proposed by Elie Metchnikoff (Nobel awarded) in 1908 
when he linked the long life and the decreasing number of chronic diseases of Bulgarian 
peasants with their utilization of fermented milk products. However, this concept was not 
clear since the bacteria within the milk were not identifiable except for ‘Bulgarian bacillus’, 
and the culture was lost.1 The word “Probiotic” was first used in 1965 by Lilley and 
Stillwell to describe substances secreted by one microorganism to stimulate the growth of 
another. 2 In 2002, World Health Organization (WHO) believed in probiotics by publishing 
guidelines to evaluate probiotics in food and they defined it as “live microorganisms which 
when administered in adequate amounts confer a health benefit on the host.” 3 
Conversely, Food and Drug Administration (FDA) approval is not required to sell probiotic 
as dietary supplements as long as there are no health claims mentioned. If probiotic is going 
to be marketed as drug to treat particular disease or disorder, it must be proven safe and 
effective for its intended use through clinical trials and approval of FDA is needed before 
it can be sold.4 
 The most common microorganisms used as probiotics are bacteria that belong to 
Lactobacillus as L.rhamnous, Bifidobacterium as B.animalis, and Streptococcus as 
streptococcus salivarius. Yeast also might be used as Saccharomyces boulardii. 5, 6    
Probiotics are naturally present in oral microflora, gut microbiota, and in food like cheese, 





different forms such as food (mostly dairy products), dietary supplements, or some 
medications. 
In the United States, 80% of manufactured yogurt had Lactobacillus and/or 
Bifidobacterium strains added as probiotics. Dietary supplements, in pill or capsule form, 
are another form of probiotics that produced by more than 80 different companies in the 
United States only.8  The possible mode of administering probiotics is very different; for 
instance, chewing gum, milk, cheese, yogurt, ice cream, drops, dust, lozenges, and 
mouthwashes. Many probiotic supplements contain 1 to 10 billion CFU per dose, but some 
contain up to 50 billion CFU or more. However, higher CFU counts do not necessarily 
improve the product’s health effects.8 
 
1.1.2 Mechanism of Action of Probiotics 
Probiotic bacteria have several impacts on the host, which was entirely based on 
gastrointestinal studies. Probiotics can influence the host immune system at both 
systematic and mucosal level, and their effect can be observed on; intestinal luminal 
environment, epithelial and mucosal barrier, and on numerous cell types involved in the 
innate and adaptive immune responses, such as epithelial cells, dendritic cells, 
monocytes/macrophages, B cells, and T cells. 9 
In order to have an effect on the host, probiotic bacteria have to be large numbers to form 
colonies. When those colonies come in touch with the epithelial cell, it will alter the cell 
surface and make it relatively hydrophilic to permit nonspecific cell binding to probiotic 
organisms. Thus, it creates thick surface-layer of protein that reduces the permeability of 





has the ability to obscure receptor binding sites and compete with pathogenic bacteria for 
substrates available to prevent pathogens from binding, invading the host and downstream 
their effect on host.10 Also, probiotic secretes bacteriocins, polypeptide antibiotic, that  help 
in preventing the growth of certain microorganisms and reduce their harmful byproducts.11 
The indirect role of probiotics is on the host immune system. It secretes substances that 
inhibit pathogen-induced cytokines resulting in a reduction of inflammation and tissue 
damage. In addition, it stimulates nonspecific immunity and modulates humoral/cellular 
immune that responds to adaptive immunity. 11, 12 
 
1.1.3 Probiotic and General Health 
Probiotics had different impacts on body systems based on their mechanism of action. In 
gastrointestinal tract, probiotics can be used as an adjunctive therapy to treat 
gastrointestinal infection, antibiotic-associated diarrheal diseases, colon cancer, food 
allergies.13 It aids in treating many diseases like vaginosis and urinary tract infections by 
creating a healthier environment within the vaginal flora.14 In addition, it used in 
cholesterol reduction by reducing cholesterol absorption through the intestinal lumen.15  In 
the liver, probiotics used to decrease total fatty acid content of the liver and reduce 
endotoxemia associated with alcoholic liver.16 lately, scientists have been associated the 
balanced diet and healthy microbiota with mental health as it improves cognitive function, 
stress management, and decision-making.17 
 
 





According to Meurman, probiotics may have an interaction in dental plaque and its almost 
identical mechanism of action as on general body systems. When administrating probiotics, 
it may aid in dental biofilm formation that contain more friendly bacteria instead of harmful 
cariogenic or periodontal bacteria, which are the cause of common oral diseases.18  It also 
may compete with pathogenic bacteria for tooth attachment and available substances to 
reduce their acidic byproducts and naturalize pH.18 Moreover, probiotic bacteria produce 
chemicals (bacitracin) that help in growth inhibition of pathogenic bacteria like S.mutans, 
Lactobacillus, A.actinomycetemcomitans, and P.gingivalis. For that, probiotics considered 
one of the oral microflora modification therapy (preventive treatment). 19, 20 
In periodontal disease, probiotics have shown to reduce all gingival and periodontal 
indexes that related to gingivitis and periodontitis, as bleeding on probing, by initiating the 
immune response to minimize the inflammatory response and secrete bacitracin that 
inhibits the growth of certain bacteria. Numerous studies have been done to evaluate 
probiotic effect on common periodontal diseases, and the relation is more believed than 
dental caries. 21, 22 
In candidal infection, candida Albicans is part of normal microflora and reasonable for 
more than 70% of fungal infections in humans, and the role of probiotics is to maintain 
homeostasis in the oral cavity and to decrease the growth of candida Albicans especially 
in the elderly.23 
In Halitosis, probiotic bacteria produce bacteriocins, which helps in reducing volatile sulfur 
compounds that responsible for malodor and maintain oral microflora. 24 
 





In dental caries, there are many studies which report the advantages of probiotics in 
management of dental caries and its risk factors, especially regarding the bacteriological 
count reduction, plaque pH control, and root caries lesions. However, only very few clinical 
research studies addressed the effect of probiotics on the S.mutans and lactobacillus counts 
in adult group.  25-27 
Juneja et al. evaluated the effect of probiotic containing milk on S.mutans count among 40 
children for 3 weeks. His results showed that there is statistically significant reduction in 
salivary mutans streptococci counts immediately after consumption of probiotics.28 
Moreover, Cildir et al. and Ashwin et al. assessed the effect of on S.mutans and 
lactobacillus counts among adolescence patients. Their results revealed statistically 
significant reduction in both bacterial counts. 29, 30 
On the other hand, Caglar et al. evaluated the probiotics effect on S.mutans and 
lactobacillus counts among young women with high S.mutans counts at the bassline for 10 
days. The results were in agreement with the previous study that there is a significant 
reduction in salivary bacterial counts. 31 
Another study was done by Srivastava et al. to evaluate the effect of probiotic curd on 
S.mutans and salivary pH on young adult for 7 days. A significant reduction was observed 











1.2.1  Caries Formation 
Dental caries is a multifactorial disease which is complicated by host environmental and 
bacterial factors.  The initiation of caries acquired action of three primary factors (tooth, 
dental plaque, and diet) that presented in a circular model in 1960s. 33  This model has been 
supplemented with factors that modulate the actions of the primary factors to determine the 
manifestation and clinical severity of caries (time, personal factors, and oral environmental 
factors). 34  
Teeth consist of a calcium phosphate mineral that demineralizes when the oral pH lowers 
(> 5.5) due to acidic bacterial byproducts. As the pH recovers, dissolved calcium and 
phosphate can reprecipitate on remaining mineral crystals (remineralization). In absence 
or lack of remineralization, caries process will progress. 35  
Dietary carbohydrates are necessary for the bacteria to produce the acids that initiate 
demineralization. In general, dietary advice for caries prevention is depend on the drop in 
pH lasts for approximately 30 minutes, frequency of intake is more important than the 
quantity, and the stickiness of foods. 34 
By clear understanding of how demineralization and remineralization occur, the role of 
fluoride and salivary minerals to buffers the acids is understood. 34 
 
1.2.2 Caries Risk Assessment 
Risk assessment is a valuable tool for the prevention and management of dental caries. 36 
The International Caries Detection and Assessment System (ICDAS) is an evidence-based 





lesion once detected, and finishes in diagnosis.37 Caries management by risk assessment 
(CAMBRA) is a methodology of identifying the cause of disease through the assessment 
of risk factors for each individual patient and then managing those risk factors through 
behavioral, chemical and minimally invasive procedures. As this approach has been widely 
used among dentists and professional organizations, it has now become a new standard of 
care which should be incorporated into the dental hygiene process of care. 38  According to 
CAMBRA, patients considered at high caries risk if they exhibit: (1) 2+ cavitated carious 
lesions diagnosed during the current examination; (2) past root caries/large number of 
exposed roots; (3) deep pits and fissures; (4) poor oral hygiene; (5) frequent sugar intake; 
(6) inadequate or no systemic or topical fluoride exposure; (7) irregular dental visits; (8) 
inadequate salivary flow; and (9) generalized white spots and/or incipient interproximal 
radiolucencies. 38 The management of those patients is to control and downstream their risk 
factors, which is highly dependent on the patient’s motivation and compliance.  
 
 
1.2.3 Role of Cariogenic Bacteria on Caries Risk 
Dental caries is a transmissible bacterial disease caused by cariogenic bacteria, streptococci 
mutans and the lactobacillus, feeding on carbohydrate. The prevalence of streptococcus 
mutans is associated with dental initiation, while lactobacilli flourish in a carious 








1.2.4 Streptococcus Mutans 
Streptococcus mutans (S.mutans) is a facultatively anaerobic, gram-positive coccus (round 
bacterium) commonly found in the human oral cavity. It is a pioneering bacterium in dental 
plaque due to its ability to attach to the tooth surface and ferment carbohydrate to produce 
acid that demineralizes tooth structures.34 S.mutans had a direct correlation with dental 
caries as it is  highly associated with caries initiation. Therefore, controlling its activity 
may have a significant impact on caries incidence. Thus, low counts of S.mutans in the oral 
cavity are good predictors of low caries risk. S.mutans levels can be quantified from a 
plaque or saliva sampling, and this procedure mostly requires a microbiological 
laboratory.34 The methods include mitis salivarius agar, glucose-sucrose-potassium-
tellurite-bacitracin agar, tryptone-yeast-cysteine-sucrose-bacitracin agar, and/or adding 
certain salts and antibacterial agents to create special agar for S.mutans culturing and 
enumeration. 39 
 
1.2.5 Mitis-Salivarius Agar  
Mitis-salivarius agar is a selective medium that developed for the isolation of S.mutans 
from human dental plaque or saliva. It is the gold standard method to isolate S.mutans. 40 
This agar can be modified by adding bacitracin, potassium tellurite, and by increasing the 
sucrose concentration to increase the selectivity of the agar to S.mutans. Those agents 
allowed the undiminished recovery of S.mutans with maximum inhibition of the balance 
of the streptococcal flora normally encountered on this medium. 39 
Bacitracin is a polypeptide antibiotic that inhibit growth of several bacteria other than 





has been used as a selective growth medium in microbiology as it inhibits most gram-
negative bacilli and most gram-positive bacteria. In a study by Srivastava et al., potassium 
tellurite and bacitracin were added to mitis-salivarius agar to count S.mutans. This 
combination was shown to be a reliable and consistent method to evaluate S.mutans.41 
There are commercially available chair-side kits to count S.mutans as Caries Risk Test, 
CariScreen, and Saliva-check mutans. They compose of mitis-salivarius agar with added 
substances as well. However, agar media made in the laboratory showed higher sensitivity 
than chair-side kits, as chairside kits may tend to grow other non-mutans organisms.42, 43 
Krasse and Fure proposed that 105 mutans streptococci per milliliter of saliva could be 
considered a high value in a person with only a few teeth and no restorations. However, 
106 might not be an extremely high value in a person with many restorations. 44  Since all 
the patients of this study are at high caries risk but not extremely high, < 5x105 has been 





1.3 Probiotics and Long-Term Effects 
There is insufficient evidence to recommend named bacteria or probiotic products for 
specific conditions. Regarding the duration, the National Institute for Health and Care 
Excellence (NICE) suggests people who are wishing to try probiotics are 
encouraged to select one brand and take it at the recommended dose for at least four weeks 
while monitoring the effect. However, no maximum duration was mentioned in all 
products.   
There are no published studies in the literature evaluating the S.mutans levels or any other 
bacteria after the suspension of the probiotic usage. The main innovative part of this study 
is assessing the extent of probiotic effect after its discontinuation. 
This study is one of very few clinical studies that directed to adult group while most caries 
related clinical researches are aiming to evaluate the inhibitory effect of probiotics on 
children or adolescence. Additionally, this study was measuring the probiotic effect of two 





1.4 Specific Aim and Hypothesis  
1.4.1 The Aim:  
The purpose of this study is to evaluate the possible inhibitory effects of commercially 
available dental probiotics usage for 60 consecutive days on the cariogenic bacterium 
S.mutans in the adult high caries risk patients with high or low S.mutans counts at baseline 
and also to determine the lingering effects after one month after the discontinuation of 
probiotic use. 
1.4.2 Hypothesis:  
1. Evaluate the level of cariogenic bacteria S.mutans inhibition when using dental 
probiotic for 60 consecutive days.  
2. Determine whether the inhibition effect on S.mutans incidence will continue at least 
one month after the last dose of probiotics. 
3. Observe and compare the inhibition effect of dental probiotics on S.mutans in 
patients with higher baseline counts versus lower baseline counts.  
1.4.3 Null Hypothesis: 
1- There is no significant difference in S.mutans count and its cariogenic activity after 
using dental probiotics for 60  consecutive days. 
2- The inhibitory effect on S.mutans will not last for 30 days after discontinuation 
probiotic. 
3- There is no difference in the inhibition effect of probiotics on S.mutans in patients 






1.5 Location of the Study:  
- Patient examination and data collection were done at Nova Southeastern University 
College of Dental Medicine (NSU CDM) Post Graduate Operative Dentistry Clinic 
and Research Clinic. 
- Agar plate preparation, saliva dilution, and bacterial culturing were done at NSU 
CDM Research Lab I, Room 7391 
-  Bacterial analysis and counting took place at NSU CDM Research Lab II, Room 
7381 
 
Nova Southeastern University 
Health Professional Division  
College of Dental Medicine 
3200 South University Drive 





2 Chapter 2: Materials and Methods 
2.1 Patient Selection and Preparation 
The study was approved by the Institutional Review Board (IRB#:2018-485-NSU) before 
starting any of the clinical and laboratory procedures. All study samples (n=30) were 
patients of record at NSU CDM, and they were evaluated for eligibility for the study 
following the caries risk determination and acceptance of their treatment plans. 
Inclusion criteria:  
• Adult population (18-99) years old. 
• High caries risk patients according to Caries Risk Management by Risk Assessment 
Protocol (CAMBRA). 38  
Exclusion criteria:  
• Pediatric or special needs patients. 
• Low caries risk patients. 
• Immune-suppressed patients.  
• Patients on long-term antibiotics. 
• Patients that are on long term antibacterial regimens (e.g. chlorhexidine). 
• Pregnant or nursing patients. 
• Edentulous patients. 
• Patients with very complex medical history or who will undergo in-patient 
treatments/ hospitalizations. 
• Patients that use hydrogen peroxide, bleaching material, or coconut oil. 





2.1 Sample Size Calculation  
This is an equivalence trial aimed to decide the sample size in this study. 
 The formula is as follows: 






𝑋	𝑝	𝑋	(1 − 𝑝) 
N=group size; p=the response rate of standard treatment group; zx= the standard 
normal deviate for two-sided test; δ0= a clinically acceptable margin. 
All parameters were assumed as follows: mean Streptococci Mutans in the treatment 
group=4706; α=0.05; β=0.20; δ0=1000, p = 60.  
From this we calculate a minimum sample size is 27-30 subjects. 
 
 
2.2 Sample Selection and Standardization:  
Subject selection, recruitment, evaluation, and all clinical/laboratory procedures 
were done by a single operator (Dr. Thanoon) for standardization and calibration 
purposes. In this study, the independent and dependent variables are described 
below:  
* Independent variables:  
Probiotics PRO-Dental tablets (Hyperbiotics Inc.; Henderson, NV). 
* Dependent variable:  








2.3 Clinical Procedures 
Subjects that fit the inclusion/exclusion criteria were approached after they accepted 
their Tx plans in PG Operative Clinic to be recruited to the study. The same operator 
(Dr. Thanoon) recruited all patients. Patients who agreed to participate were given a 
consent form to sign (Figure 23). 
Patients were told that they would be enrolled after their periodontal cleaning is 
completed and before their Fluoride treatments began. As an incentive, patients were 
informed that they would receive 4 bacterial tests during this study = $100/each 
($400) and 60 probiotic tablets were given free of charge to each patient = $45 
(Total= $445/each patient). 
Patients were informed that they would be dropped out of the study if they no longer 
meet the criteria as taking antibiotics or antibacterial therapy, fail to show up to 
scheduled appointments, and fail to follow the study directions e.g., stop using 
probiotic for three consecutive days. 
 
2.3.1 1st visit – Baseline-Initial procedures 
Subjects that fit the inclusion/exclusion criteria and who agreed to participate and 
signed the consent presented back after they received periodontal cleaning to be 
enrolled in the study.  
At the baseline visit, accepted patients had standard oral hygiene instructions and 





Gamble, Cincinnati, Ohio)), toothpaste (Colgate total (Colgate, New York City, 
NY)) and dental floss (Oral-B Glide (The Procter and Gamble, Cincinnati, Ohio). 
Medical history was checked. Then, clinical examination was performed to each 
patient in order to count DMFT scores (decayed, missing, filled teeth according to 
the modified dental caries index by Bodecker) and conifer their caries risk 
assessment. All subjects presented having eaten at least an hour before saliva 
collection. After the collection of the saliva samples, patient requested to start using 
the dispensed probiotic tablets (60 tablets) starting with that night following the 
verbal and written instruction (take 1 chewable tablet at bedtime, after brushing and 
flossing your teeth, please refrain from eating and drinking until the next morning). 
This protocol is to be continued for 60 consecutive days, but patients need to be 
present for the follow up after 30 days. Patients were given a diary log sheet as a 
reminder and which they were asked to mark every time they used probiotic. They 













2.3.2 1st visit – Baseline- Saliva collection 
Patients were requested to chew the paraffin wax for about 3-4 minutes to stimulate 
salivation. Then, they were asked to spit out saliva (1ml) in a sterile container. 
Saliva samples were identified by giving a code number which was written on the 
collecting bottle, using a waterproof pen. The collected salivary sample was then 
be transported to the laboratory (Research Lab I, Room 7391, NSU CDM) 
immediately and processed within 6 hours (Figure 2). 
 
 






2.3.3. 1st visit – Baseline – Probiotic Distribution 
The patients were blinded to the probiotic brand and were handed out capsules in 
generic bottles with customized labels. The probiotic tablets used were PRO-Dental 
Probiotic (Company name (Hyperbiotics whatever); full addressHenderson, NV). 
Patients were informed that these pribiotics are commercially available, they are 
made in the USA in a certified Good Manufacturing Practice (GMP) facility. They 
are also lactose-free, vegetarian, non-GMO, yeast free, no lactose, no soy, no iron, 
no gluten, no wheat, no nuts, no preservatives Contents of 1 tablet include Zinc 
2mg and Proprietary Probiotics Blend of 3 billion CFU (S. salivarius K 
12, S.Salivarius M 18, L. reuteri, L paracasei). (Figure 3). (Figure 4). 2mg and 
Proprietary Probiotics Blend of 3 billion CFU (S. salivarius K 12, S.Salivarius M 






















2.3.2 2nd visit (30 days after using probiotics): (change number) 
After 30 consecutive days of probiotic usage, patients reported back to NSU CDM 
PG Operative Dentistry Clinic/Research Clinic having eaten at least an hour where 
saliva collection was done for microbiological analysis. Medical history was 
updated. Patients were reminded to continue to take the probiotic tablets, oral 
hygiene instructions were reviewed verbally, and log sheet was checked. Patients 
were asked if they demonstrated any symptoms or any side effects throughout this 
study period. 
Saliva samples were collected and analyzed using the same methods of initial visit.  
 
2.3.3 3rd visit (60 days after using probiotics): 
Patients reported back to NSU PG Operative Dentistry Clinic/Research Clinic 
having eaten at least an hour where saliva collection was done for microbiological 
analysis. Medical history was updated. Patients were asked to discontinue the 
probiotics, oral hygiene instructions were reviewed verbally, and log sheet was 
checked. Patients were asked if they demonstrated any symptoms or any side effects 
throughout this study period. Saliva samples were collected and analyzed using the 








2.3.4 4th visit – final visit (30 days after discontinuation of using 
probiotics): 
Patients reported back to NSU PG Operative Dentistry Clinic/Research Clinic where 
saliva collection was done for microbiological analysis for the last time. Medical 
history was updated. Oral hygiene instructions and home care techniques were 
reviewed to make sure that you are maintaining good oral hygiene. Clinical 
examination was performed and, DMFT was recounted. Since the patients at high 
caries risk, they were told to resume their preventive dentistry treatments such as 
Fluoride varnish, high Fluoride toothpaste, MI paste. Patient’s compliance check was 
performed. Patients received 60 days’ supply of probiotic tablets at the beginning of 
the study. To assess compliance, the number of remaining tablets returned by each 
patient was counted to confirm the missed consumption of probiotics. All study 
samples (n=30) were able to show up in baseline and recall appointments. Patients 
demonstrated no symptoms or any side effects throughout study period. 
 
2.4 Laboratory Procedures 
2.4.1 Mitis-salivarius Bacitracin Potassium-tellurite agar Preparation 
Mitis salivarius (Sigma Aldrich (St. Louis, MO)) media was prepared as the 
following: 
- Suspend 9.07 grams of mitis- salivarius in 100 ml of distilled water (Figure 5). 
- Heat to boiling to dissolve the medium completely using thermal mixer (VWR, 





- Dispense and sterilize by autoclaving at 15 lbs. pressure (121°C) for 30 minutes 
(Tuttnauer, NY) (Figure 7). 
- Cool to 50-55°C and transfer it to biosafety cabinet in sterile conditions to 
eliminate contamination (Labconco, VWR (Radnor, PA)) (Figure 8). 
- In the cabinet, mix 0.01 gm of potassium tellurite (Sigma Aldrich (St. Louis, MO)) 
in 1 ml of distilled water (Figure 9). 
- In the cabinet, mix 0.002 gm of bacitracin (Sigma Aldrich (St. Louis, MO)) in 1 
ml distilled water (Figure 10). 
- After cooling the agar media, add 100 µl of potassium tellurite and 150 µl of 
bacitracin in a sterile environment.  
- Do not reheat the medium after adding potassium tellurite and bacitracin 
- Mix well and pour into sterile petri dishes 15mm (VWR (Radnor, PA)) (Figure 
11) 
- Wait till it cool down completely before incubation 
- if not used in the same day, wrap it well and keep it in the refrigerator at 2-8 °C. 
• Quality Control 












Figure 7. Thermal mixer 









Figure 8. Potassium tellurite 








Figure 10. Biosafety cabinet 





2.4.2 Saliva Dilution and Incubation 
Saliva dilution is an essential step in S.mutans incubation since the later presented 
in human saliva in large numbers. Thus, in order to get countable numbers of 
S.mutans, saliva needs to be diluted. In this study, saliva was diluted to 100, 1000 
and 10,000 times in phosphate buffered saline (PBS) 7.4 pH (Thermo Fisher 
scientific, Weston, FL) (Figure 12).  
Saliva sample was vortexed using vortex mixer (VWR, Radnor, PA) for 15 sec. and 
transferred to biosafety cabinet. 
 





• Saliva was diluted as following: 
- 10 µl of saliva was added to 990 µl of PBS to get 100-time diluted saliva.  
- 100-time diluted saliva was added to 900 µl of PBS to get 1000-time diluted saliva. 
- 1000-time diluted saliva was added to 900 µl of PBS to get 10000-time diluted saliva. 
 
• Saliva incubation  
Serially diluted bacterial suspensions were inoculated to mitis-salivarius-
bacitracin-potassium-tellurite agar plates (50 ml each). In order to control sterility 
of agar plates, 50 ml of clear PBS was plated in each incubation. Incubation of all 
agar was carried out in an anaerobic jar at 37°C for 48 h (VWR (Radnor, PA)) 
(Figure 13). After 48h, Petri dishes were transferred to laminar flow cabinet (Air 
Science, Fort Myers, FL) for S.mutans colonies observing and counting using 
colony-forming units (CFUs) at different dilution factors (Figure 14,15,16,17). PBS 
plate was clear (no colonies observed) in every incubation (Figure 18). 
Counted S.mutans colonies were calculated based on the following equation:  






Figure 14. VWR incubator 







Figure 15. S.mutans colonies observed on 100-time diluted saliva 








Figure 18. PBS plate - no colonies 







2.5 Statistical Analysis:  
 Poisson distribution was used to account for the data measurement scale. Pairwise 
comparisons of margins with a Bonferroni adjustment were used to look for specific 
differences across time periods. A significance level of 0.05 was used for all tests. Pairwise 





Chapter 3: Results 
Four mixed generalized liner models were conducted to observe the differences in probiotic 
count in attenuated saliva at 100, 1000, 10000 dilution factors, and baseline over time. The 
fixed effects were time (baseline, 2nd visit, 3rd, 4th visit) and sex (female, male. The 
random effect was the subject. Poisson distribution was used also to account for the data 
measurement scale. The results show that there is a significant reduction in S.mutans counts 
after using probiotics for 60 consecutive days and even after its suspension for 30 days (p 
< 0.05).  
The reduction was observed at all saliva dilution factors 100, 1000, and 10000. However, 
there was no distinction between male and female patients. Considering the average 
numbers, the highest difference in S.mutans counts were found between baseline 
(mean=881440) and third visit (60 days after using probiotics) (mean=244817) (Table 1). 
Pairwise comparisons of margins with a Bonferroni adjustment was used to look for 
specific differences across time periods, baseline (before using probiotics), 2nd visit (30 
days of using probiotics), 3rd visit (60 days of using probiotics), and 4th visit (30 days after 
stop using probiotics). Statistically significant difference were found between baseline and 
2nd visit, baseline and 3rd visit, and 2nd and 3rd visit (p < 0.0001). However, there is no 
statistically difference between 3rd and 4th visit. Moreover, the great difference between 
baseline and 4th visit (p < 0.0001) proof that the effect of probiotic on S.mutans counts 


















Margin plots were created to show the reduction in S.mutans numbers (the mean values 
were considered) at different dilution factors and the average of all factors. Reflecting the 
average values, S.mutans counts dropped by %48.5 from baseline to 2nd visit (30 days of 
using probiotics) and continued to decrease by %35.4  from 2nd to 3rd visit (60 days of using 
probiotics). Accordingly, the total reduction of S.mutans count after 60 days of probiotic 
usage is %83.9. However, it got slightly increased by %14.4 from 3rd to 4th visit (30 days 
after using probiotics), but still significantly reduced compared to baseline counts (%69.5) 
(P<0.05) (Figure 19-21) (Table 3). 
 
As it was determined whether S.mutans counts were high or low at baseline visit based on 
value of (5x105/1ml of saliva), %77 of patients presented with high S.mutans counts at the 
baseline. However, after 30 days of probiotic usage, only %20 of patients had high 
S.mutans counts. After 60 days of using probiotics and 30 days after probiotics 
discontinuation, all patients presented with low S.mutans counts. 
 
In addition, results illustrate that patients presented with high DMFT counts demonstrated 
higher S.mutans counts at the baseline. Still, no statistical difference found between 
gender. After 60 days of probiotic usage, patients presented with high DMFT scores 
and S.mutans count at the baseline showed a significant reduction in the S.mutans counts 
while DMFT scores were still the same.  
 
Patients were able to present in all appointments (Compliance rate %100). Probiotic tablet 





retuned bottles, and it exceeded 90% over the 60 days, indicating perfect compliance. No 







































Chapter 4: Discussion 
The first null hypothesis that there is no significant difference in S. mutans count after using 
dental probiotics (PRO-Dental) for 60 consecutive days must be rejected. In the present 
study, S mutans count decreased by %83.9 after 60 days of probiotic usage. This study has 
no control group, yet findings were corroborated by many previous studies that evaluated 
S.mutans level in saliva after oral probiotic therapy in both adults and children, using 
different probiotic strains. 26-32 Additionally, this study was directed to the adult group 
while most of caries related clinical research aimed to evaluate the inhibitory effect of 
probiotics on children or adolescents. This clinical study evaluated the S.mutans counts 
after 60 days of probiotics usage, which consider to be relatively long period comparing to 
similar studies. 
 
Conversely, some studies contradicted the findings of this study, as they reported no 
changes in salivary S.mutans levels after probiotic administration.45, 46 Gizani et al. 
evaluated the effect of 2 strains of Lactobacillus reuteri on salivary S.mutans, L.bacillus, 
and white spot lesions among orthodontic patients after debonding. In their results, there 
was a significant reduction in L.bacillus counts while no noticeable changes in the S.mutans 
counts were unveiled. This conclusion opposed several studies, including the present 
study.46  
 
This study is unique as it evaluated the prolonged effect of probiotic on the S.mutans levels 





evaluated that prolonged effect of any probiotic strains on S.mutans or any other bacteria. 
Furthermore, no studies or dietary products recommended the duration of probiotic usage.  
The study finding revealed that S.mutans level got increased by %14.4 from 3rd (60 days 
of probiotic usage) to 4th visit (30 days after probiotic discontinuation), although still 
significantly reduced compared to baseline counts (%69.5) (P<0.05). Thus, the second null 
hypothesis that the inhibitory effect on S.mutans will not last 30 days after probiotic 
discontinuation was rejected as well.  
 
Study findings indicate that from baseline to 1st visit (30 days of probiotic usage), patients 
presented with high S.mutans counts at the baseline showed higher reduction in bacterial 
counts comparing to low S.mutans counts. However, in the following appointments, there 
was no difference in the inhibition effect of probiotics on S.mutans in patients with higher 
vs. lower baseline counts. As only high caries risk patients were included in the study, it 
can be concluded that patients with low S.mutans counts still can be at high caries risk.  
No studies have been reported the effect of (PRO-Dental) probiotic on S.mutans before the 
present study. Based on the results and patients’ feedback, it has been shown that (PRO-
Dental) probiotics can be used safely and that tablets are an easy and acceptable vehicle 
for probiotic administration, as demonstrated by the high compliance. 
Mitis-salivarius agar with added bacitracin and potassium tellurite that increased selectivity 
of the media toward S.mutans showed to be very consistent and reliable method since each 







There were unavoidable limitations. In the study, samples were recruited conveniently 
since all patients were NSU-CDM patients. Additionally, one type of probiotics (PRO-
Dental) that contained 4 different bacterial strains was used and the effect on S.mutans 
could not be related to certain strain.  Another limitation is that only S.mutans colonies 
were evaluated in this study. However, L.bacillus is related to caries as well by its role in 
caries progression. Thus, further studies are needed to evaluate the immediate and 
prolonged effect of probiotic on L.bacillus. Moreover, the results suggest the correlation 






Chapter 5: Conclusion 
According to the results of this study, the daily administration of dental probiotics for two 
months sufficiently suppressed the level of oral S.mutans. However, further long-term 
research is needed to evaluate the sustainability of probiotics on the continued suppression 
of this cariogenic bacterium. It is also important to clarify that probiotics are an additional 
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